WAM
RXRX icon

Weiss Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Weiss Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,880
Closed -$272K – 871
2021
Q4 		$272K Buy
+15,880
New +$299K 0.01% 588

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Weiss Asset Management's RXRX Position: Q1 2022 in Review

Weiss Asset Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2022, closing a stake of 15,880 shares — an estimated $272K sold.

Weiss Asset Management first reported a position in RXRX in Q4 2021 and held it in 1 quarter. The position peaked at $272K in Q4 2021. 128 funds tracked by Wall St. Rank hold RXRX as of Q1 2022.

  • Weiss Asset Management reported no remaining Recursion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Weiss Asset Management sold 15,880 Recursion Pharmaceuticals shares in Q1 2022, an estimated $272K.
  • Weiss Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Weiss Asset Management's Recursion Pharmaceuticals position peaked at $272K in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2022.

Based on Weiss Asset Management's 13F filing for Q1 2022, filed 13 May 2022.